Abstract
Approximately 50% of patients with heart failure have a normal or almost normal ejection fraction, referred to variably as diastolic heart failure or heart failure with preserved ejection fraction (HFpEF). The prevalence of this condition is likely to keep increasing as the prevalence of the elderly with comorbid conditions increases. HFpEF is associated with substantial morbidity and mortality. There exists an urgent need to identify effective treatment strategies for the management of patients with HFpEF. This chapter provides an overview of therapeutic modalities that could be effective in patients with HFpEF based either on symptomatic benefit or on targeting pathophysiologic mechanisms. The clinical approach to management of these patients with HFpEF is summarized based on current evidence and consensus opinion.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call